Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

ceramide pathway

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Akt (1) Apoptosis (6) Autophagy (1) CDK (1) Endogenous Metabolite (2) Fungal (1) FXR (1) Isotope-Labeled Compounds (3) JNK (1) mTOR (2) p38 MAPK (1) Phosphatase (1) Reactive Oxygen Species (ROS) (1) Survivin (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (5)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Tissue Factor Pathway Inhibitor (TFPI)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100355

C18-Ceramide (d18:1/18:0) C18-ceramide	Endogenous Metabolite	Neurological Disease Cancer
C18-Ceramide (d18:1/18:0) is a bioactive molecule with multiple functions in cells, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology .

HY-N9933

Tauro-β-muricholic acid 4 Publications Verification TβMCA	FXR Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC₅₀=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis .

HY-19542

C6 Ceramide 3 Publications Verification C6-Cer; N-Hexanoylsphingosine	Apoptosis	Cancer
C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

HY-134508

C24-Ceramide	mTOR	Neurological Disease Cancer
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .

HY-170035

GlcCer (d18:1/18:0) C18 Glucosyl(β) ceramide (d18:1/18:0); D-glucosyl-β-1,1' N-stearoyl-D-erythro-sphingosine	Fungal Wnt β-catenin	Infection Neurological Disease Cancer
GlcCer (d18:1/18:0) (C18 Glucosyl(β) ceramide (d18:1/18:0)) is a glycosphingolipids that activates the Wnt/β-catenin pathway by targeting LRP6. GlcCer (d18:1/18:0) drives EMT, migration, invasion and GBA1-mediated liver cancer metastasis. GlcCer (d18:1/18:0) accumulates to impair lysosomal function and induce toxic α-synuclein aggregation. GlcCer (d18:1/18:0) supports growth, sporulation, germination and virulence in Penicillium digitatum. GlcCer (d18:1/18:0) is reduced in demyelinated mouse corpus callosum. GlcCer (d18:1/18:0) can be used for the research of liver cancer, synucleinopathies, fungal, Parkinson’s disease and Gaucher disease .

HY-125953

Ceramide (Egg) ceramide (Egg, Chicken)	JNK p38 MAPK Phosphatase Akt Survivin CDK mTOR Apoptosis Autophagy Reactive Oxygen Species (ROS)	Neurological Disease Cancer
Ceramide (Egg) (Ceramide (Egg, Chicken)) is a ceramide from chicken. Ceramide (Egg) is a sphingomyelin signaling pathway second messenger. Ceramide (Egg) activates PP2A, JNK, p38 MAPK, CAPK, ceramide-activated protein phosphatase, Vav, PKCζ, and SAPK/JNK cascade. Ceramide (Egg) downregulates or inhibits AKT, survivin, CDK2, mTOR, and FLIP. Ceramide (Egg) mediates apoptosis, autophagy, cell cycle arrest, mitochondrial dysfunction, redox state shifts, and ROS generation. Ceramide (Egg) can be used for the research of cancer and neurological disease .

HY-19542S1

C6 Ceramide-d11 C6-Cer-d₁₁; N-Hexanoylsphingosine-d₁₁	Apoptosis Isotope-Labeled Compounds	Cancer
C6 Ceramide-d₁₁ is deuterated labeled C6 Ceramide (HY-19542). C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

HY-19542S

Ceramide C6-d7	Isotope-Labeled Compounds Apoptosis	Cancer
Ceramide C6-d₇ is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells .

HY-W766368

C6 Ceramide-13C2,d2 C6-Cer-¹³C₂,d₂; N-Hexanoylsphingosine-¹³C₂,d₂	Isotope-Labeled Compounds Apoptosis	Cancer
C6 Ceramide- ¹³C₂,d₂ (C6-Cer- ¹³C₂,d₂) is the deuterium labeled and ¹³C-labeled C6 Ceramide (HY-19542). C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

HY-181943

SPT-IN-2	Acyltransferase	Cancer
SPT-IN-2 is an orally active serine palmitoyltransferase (SPT) inhibitor (with an IC₅₀ of 0.71 nM against human SPT2). SPT-IN-2 inhibits ceramide synthesis, suppresses cancer cell growth, and exhibits in vivo anti-tumor activity, favorable metabolic stability and cell membrane permeability in xenograft mouse models. SPT-IN-2 blocks the de novo sphingolipid synthesis pathway, significantly reducing intracellular ceramide levels and the levels of 3-ketodihydrosphingosine (3-KDS), the immediate downstream product of SPT. SPT-IN-2 can be used in research related to lung adenocarcinoma, acute promyelocytic leukemia and breast cancer .

HY-N10706

3-Keto sphinganine (d18:0)	Endogenous Metabolite	Cardiovascular Disease
3-Keto sphinganine (d18:0) serves as the substrate for 3-keto-dihydrosphingosine reductase in the de novo sphingolipid synthesis pathway, and is a key intermediate in the de novo synthesis of sphingoid long-chain bases. 3-Keto sphinganine (d18:0) can be used in studies related to thrombocytopenia, anemia .

Cat. No.	Product Name	Type

HY-134508

C24-Ceramide	Biochemical Assay Reagents
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .

C24-Ceramide

Biochemical Assay Reagents

C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-100355

C18-Ceramide (d18:1/18:0) C18-ceramide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
C18-Ceramide (d18:1/18:0) is a bioactive molecule with multiple functions in cells, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology .

HY-N9933

Tauro-β-muricholic acid 4 Publications Verification TβMCA	Structural Classification Human Gut Microbiota Metabolites Animals Endogenous metabolite Steroids Source Classification	FXR Apoptosis
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC₅₀=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis .

HY-N10706

3-Keto sphinganine (d18:0)	Structural Classification Natural Products Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite
3-Keto sphinganine (d18:0) serves as the substrate for 3-keto-dihydrosphingosine reductase in the de novo sphingolipid synthesis pathway, and is a key intermediate in the de novo synthesis of sphingoid long-chain bases. 3-Keto sphinganine (d18:0) can be used in studies related to thrombocytopenia, anemia .

Cat. No.	Product Name	Chemical Structure

HY-19542S1

C6 Ceramide-d11
C6 Ceramide-d₁₁ is deuterated labeled C6 Ceramide (HY-19542). C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

HY-19542S

Ceramide C6-d7
Ceramide C6-d₇ is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells .

HY-W766368

C6 Ceramide-13C2,d2
C6 Ceramide- ¹³C₂,d₂ (C6-Cer- ¹³C₂,d₂) is the deuterium labeled and ¹³C-labeled C6 Ceramide (HY-19542). C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

C6 Ceramide-13C2,d2

C6 Ceramide- ¹³C₂,d₂ (C6-Cer- ¹³C₂,d₂) is the deuterium labeled and ¹³C-labeled C6 Ceramide (HY-19542). C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

Cat. No.	Product Name		Classification

HY-134508

C24-Ceramide		Phospholipids
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

ceramide pathway

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products